On Jun. 7 1999, NeoPath merged with AutoCyte to form TriPath Imaging based in Burlington, N.C. NeoPath was a university of Washington spin-off co-founded by Gordon Kuenster, that made the AutoPap automated screening system for cervical cancer, and AutoCyte developed a system that produced slides with a thin layer of cervical cells, an alternative approach to the standard Pap smear. Each NeoPath share was exchanged for 0.79 shares of AutoCyte, worth $6.12 at its closing price.